Aradigm Receives Feedback Following an Oral Explanation With the European Medicines Agency
NEWARK, Calif.–(BUSINESS WIRE)–Aradigm Corporation (OTCQB: ARDM) (“Aradigm” or the “Company”) today announced that following a recent Oral Explanation, it has
North America
FDA approves AstraZenecas Farxiga for reducing hospitalisation for heart failure in type 2 diabetes patients
AstraZeneca on Monday said that that the US Food and Drug Administration (FDA) has approved Farxiga (dapagliflozin) to reduce the risk of hospitalisation for heart failure (hHF) in adults with type-2 diabetes (T2D) and established cardiovascular disease (CVD) or multiple cardiovascular (CV) risk factors.
Europe
Spanish Government Approves National Reimbursement of Orkambi and Symekevi in Combination With Kalydeco
LONDON–(BUSINESS WIRE)–Vertex Pharmaceuticals Incorporated (NASDAQ: VRTX) today announced that the Spanish Government has approved terms for the national reimbursement of
